CSIMarket



Worst Performing Stocks In Biotechnology & Pharmaceuticals Industry During This Current Quarter Q2 Of 2024



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares are up by 1.38% on average, in Biotechnology & Pharmaceuticals Industry during this current quarter q2 of 2024.

Here are the Worst performing stocks in Biotechnology & Pharmaceuticals Industry.




GILD

$64.59

$-10.7300 -14.25%
This Quarter Q2 of 2024


GILD

$64.59

$-10.7300 -14.25%



Gilead Sciences Inc

Gilead Sciences Inc shares dropped -14.25% during this current quarter q2 of 2024.


Gilead Sciences Inc*s business model revolves around researching, developing, and commercializing innovative medicines in various therapeutic areas, with a primary focus on antiviral drugs. They aim to address unmet medical needs and improve the lives of patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 80,543.730 mill. $ 27,450.000 mill. $ 458.000 mill. 1,247 mill. 178.34 Y/Y 5.26 %
Market Cap. Revenues TTM Net Income TTM

$ 80,543.730 mill.


$ 27,450.000 mill.


$ 458.000 mill.

Employees Shares Outstanding P/E

14,400


1,247 mill.


178.34

Revenue Growth Income Growth

MRQ Y/Y 5.26 %


MRQ Y/Y - %



ARGX

$385.87

$0.8700 0.23%
This Quarter Q2 of 2024


ARGX

$385.87

$0.8700 0.23%



Argenx se

Argenx Se shares went up 0.23% during this current quarter q2 of 2024.


Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 22,059.900 mill. $ 2,494.910 mill. $ -295.053 mill. 57 mill. - Y/Y 191.46 %
Market Cap. Revenues TTM Net Income TTM

$ 22,059.900 mill.


$ 2,494.910 mill.


$ -295.053 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 191.46 %


MRQ Y/Y - %



BIIB

$231.41

$1.3400 0.58%
This Quarter Q2 of 2024


BIIB

$231.41

$1.3400 0.58%



Biogen Inc

Biogen Inc shares increased 0.58% during this current quarter q2 of 2024.


Biogen Inc*s business model revolves around researching, developing, and commercializing therapies for neurological and neurodegenerative diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 33,762.719 mill. $ 9,663.100 mill. $ 1,167.300 mill. 146 mill. 28.93 Y/Y -7.00 %
Market Cap. Revenues TTM Net Income TTM

$ 33,762.719 mill.


$ 9,663.100 mill.


$ 1,167.300 mill.

Employees Shares Outstanding P/E

9,610


146 mill.


28.93

Revenue Growth Income Growth

MRQ Y/Y -7.00 %


MRQ Y/Y 1.50 %



AMGN

$297.25

$21.8900 7.95%
This Quarter Q2 of 2024


AMGN

$297.25

$21.8900 7.95%



Amgen Inc

Amgen Inc stock improved 7.95% during this current quarter q2 of 2024.


Amgen Inc*s business model is centered around developing, manufacturing, and commercializing innovative biotechnology products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 159,326.000 mill. $ 29,532.000 mill. $ 3,763.000 mill. 536 mill. 42.45 Y/Y 21.98 %
Market Cap. Revenues TTM Net Income TTM

$ 159,326.000 mill.


$ 29,532.000 mill.


$ 3,763.000 mill.

Employees Shares Outstanding P/E

24,200


536 mill.


42.45

Revenue Growth Income Growth

MRQ Y/Y 21.98 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com